Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative
暂无分享,去创建一个
D C Wheeler | B. Kasiske | F. Cosio | A. Levin | C. Wanner | D. Wheeler | P. Wilson | B. Chavers | R. Grimm | K. Bolton | R. Parekh | J. Beto | B Kasiske | F G Cosio | J Beto | K Bolton | B M Chavers | R Grimm | A Levin | B Masri | R Parekh | C Wanner | P W F Wilson | A. Levin | B. Masri | F.G. Cosio | B.M. Chavers
[1] J. Cazenave,et al. Cardiovascular morbidity and endothelial dysfunction in chronic haemodialysis patients: is homocyst(e)ine the missing link? , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[2] A. Clayton,et al. A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). , 2000, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[3] E. Braunwald,et al. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. , 2002, The American journal of cardiology.
[4] L. Gibbons,et al. The prevalence of side effects with regular and sustained-release nicotinic acid. , 1995, The American journal of medicine.
[5] G. Lipkin,et al. Severe reversible renal failure with bezafibrate , 1993, The Lancet.
[6] P. Allhoff,et al. Bogalusa Heart Study , 2020, Encyclopedia of Behavioral Medicine.
[7] M. Taskinen,et al. Pathology of renal arteries of dyslipidemic children with congenital nephrosis , 1994, Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS).
[8] C. Glueck,et al. Severe depression of high-density lipoprotein cholesterol levels in weight lifters and body builders by self-administered exogenous testosterone and anabolic-androgenic steroids. , 1984, Metabolism: clinical and experimental.
[9] S. Papacostas. Oxcarbazepine Versus Carbamazepine Treatment and Induction of Serum Lipid Abnormalities , 2000, Journal of child neurology.
[10] R. Foley,et al. Clinical epidemiology of cardiovascular disease in chronic renal disease. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[11] S. Olson,et al. Renal Dysfunction Does Not Alter the Pharmacokinetics or LDL‐Cholesterol Reduction of Atorvastatin , 1997, Journal of clinical pharmacology.
[12] M. Laudat,et al. Plasma lipids, lipoproteins and apolipoproteins AI, AII, and B in renal transplanted children: what risk for accelerated atherosclerosis? , 1984, Nephron.
[13] W. März,et al. Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. , 1999, Kidney international. Supplement.
[14] U. P. S. T. Force,et al. Measuring Quality: Are We Ready To Compare the Quality of Care among Physician Groups? , 2002, Annals of Internal Medicine.
[15] W. Weimar,et al. Increased low density lipoprotein oxidation in stable kidney transplant recipients. , 1996, Kidney international.
[16] P. Neuvonen,et al. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin , 1999, Clinical pharmacology and therapeutics.
[17] J. Lloyd,et al. Double blind trial of bezafibrate in familial hypercholesterolaemia. , 1985, Archives of disease in childhood.
[18] M. Hirai,et al. Elevated Blood Concentrations of Cyclosporine and Kidney Failure after Bezafibrate in Renal Graft Recipient , 1996, The Annals of pharmacotherapy.
[19] R. Luke,et al. Effect of alternate-day prednisone on plasma lipids in renal transplant recipients. , 1982, Kidney international.
[20] E. Janus,et al. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy , 2004, Diabetologia.
[21] F. Figueras,et al. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. , 2000, Maturitas.
[22] M. Praga,et al. [Effect of pravastatin on hypercholesterolemia associated with proteinuria]. , 1994, Anales de medicina interna.
[23] C. Derby,et al. Cardiovascular risk profiles of oral contraceptive users and nonusers: a population-based study. , 1995, Preventive medicine.
[24] C. Castaneda,et al. Potential benefits of resistance exercise training on nutritional status in renal failure. , 1998, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.
[25] P. Neuvonen,et al. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations , 2000, European Journal of Clinical Pharmacology.
[26] A. Hofman,et al. Do oral contraceptives increase blood pressure and serum total cholesterol in young women? , 1990, Preventive medicine.
[27] K. Ivens,et al. Cardiovascular risk factors and diseases after renal transplantation , 2006, International Urology and Nephrology.
[28] R. Zietse,et al. Cholesterol as an independent predictor of outcome after renal transplantation. , 2000, Transplantation.
[29] B. Kasiske,et al. Effect of lipid reduction on the progression of renal disease: a meta-analysis. , 2001, Kidney international.
[30] P. O'Brien,et al. Hyperlipidemia in patients with primary and secondary hypothyroidism. , 1993, Mayo Clinic proceedings.
[31] S. Katznelson,et al. The effect of pravastatin on acute rejection after kidney transplantation--a pilot study. , 1996, Transplantation.
[32] C. Glueck,et al. Severe hypertriglyceridemia and pancreatitis when estrogen replacement therapy is given to hypertriglyceridemic women. , 1994, The Journal of laboratory and clinical medicine.
[33] Terje R Pedersen,et al. Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) , 1997, Diabetes Care.
[34] D. Wheeler,et al. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. , 2001, Kidney international.
[35] Y. Ueda,et al. Effects of Combination Therapy Consisting of Moderate-Dose Intravenous Immunoglobulin G,Pulsed Methylprednisolone and Pravastatin inChildren with Steroid-Resistant Nephrosis , 2000, Nephron.
[36] D. Hunninghake,et al. Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE)-rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease. , 2000, The American journal of cardiology.
[37] R. Wolfe,et al. Cardiovascular mortality in children and young adults with end-stage kidney disease. , 2002, The Journal of pediatrics.
[38] W. März,et al. Is the determination of LDL cholesterol according to Friedewald accurate in CAPD and HD patients? , 1996, Clinical nephrology.
[39] R. Schmieder,et al. Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[40] F. V. Lente,et al. Serum lipid changes associated with modified protein diets: results from the feasibility phase of the Modification of Diet in Renal Disease Study. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[41] H. Parving,et al. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy , 1992, Diabetologia.
[42] D. Hunninghake,et al. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. , 2001, Atherosclerosis.
[43] H. H. Chen,et al. Recurrent pancreatitis secondary to type V hyperlipidemia: report of one case. , 2000, Acta paediatrica Taiwanica = Taiwan er ke yi xue hui za zhi.
[44] S. Sanjad,et al. Management of hyperlipidemia in children with refractory nephrotic syndrome: the effect of statin therapy. , 1997, The Journal of pediatrics.
[45] D. Seidel. Hyperlipoproteinemias and liver disease. , 1973, Advances in experimental medicine and biology.
[46] W. Castelli,et al. ALCOHOL AND BLOOD LIPIDS The Cooperative Lipoprotein Phenotyping Study , 1977, The Lancet.
[47] R. J. Simpson. Placing PRINCE in perspective. , 2001, JAMA.
[48] P. Allhoff,et al. The Lipid Research Clinics Program Prevalence Study. , 1980, Circulation.
[49] B. Kasiske,et al. THE EFFECTS OF LIPID-LOWERING AGENTS ON ACUTE RENAL ALLOGRAFT REJECTION1, 2 , 2001, Transplantation.
[50] B. Davis,et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. , 1998, Circulation.
[51] M. Siimes,et al. Sitostanol ester margarine in dietary treatment of children with familial hypercholesterolemia. , 1995, Journal of lipid research.
[52] J. Lloyd,et al. The effect of cholestyramine on intestinal absorption. , 1975, Gut.
[53] S. Hall,et al. The interaction of diltiazem with lovastatin and pravastatin , 1998, Clinical pharmacology and therapeutics.
[54] J. Joven,et al. The influence of hypoalbuminemia in the generation of nephrotic hyperlipidemia. , 1996, Atherosclerosis.
[55] R. Goldberg,et al. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. , 1996, Transplantation.
[56] Betteridge. Diabetic dyslipidaemia , 1999, Diabetes, obesity & metabolism.
[57] M. A. Lasunción,et al. Cholesteryl ester transfer activity in liver disease and cholestasis, and its relation with fatty acid composition of lipoprotein lipids. , 1996, Clinica chimica acta; international journal of clinical chemistry.
[58] W. G. Walker. Hypertension-related renal injury: a major contributor to end-stage renal disease. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[59] A. Keogh,et al. Comparison of three immunosuppressive protocols in cardiac transplantation. , 1989, Transplantation proceedings.
[60] P. Mulrow,et al. Changes in cholesterol levels after coronary artery bypass surgery. , 1992, The American journal of the medical sciences.
[61] J. Strong,et al. Effects of coronary heart disease risk factors on atherosclerosis of selected regions of the aorta and right coronary artery. PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[62] J. S. Wang,et al. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[63] F. Berthoux,et al. Results of a 1-year randomized controlled trial with omega-3 fatty acid fish oil in renal transplantation under triple immunosuppressive therapy. , 1995, Transplantation proceedings.
[64] R. Tracy,et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. , 1998, The New England journal of medicine.
[65] J. Weststrate,et al. Plant sterol-enriched margarines and reduction of plasma total- and LDL-cholesterol concentrations in normocholesterolaemic and mildly hypercholesterolaemic subjects , 1998, European Journal of Clinical Nutrition.
[66] B. Kasiske,et al. Explained and unexplained ischemic heart disease risk after renal transplantation. , 2000, Journal of the American Society of Nephrology : JASN.
[67] C. Barbagallo,et al. CAROTID ATHEROSCLEROSIS IN RENAL TRANSPLANT RECIPIENTS , 2000 .
[68] Z. Massy,et al. Carotid atherosclerosis in renal transplant recipients. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[69] Ronald M. Lauer,et al. National Cholesterol Education Program. Report of the Expert Panel on Population Strategies for Blood Cholesterol Reduction: executive summary. National Heart, Lung and Blood Institute, National Institutes of Health. , 1991, Archives of internal medicine.
[70] Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. , 2001, The New England journal of medicine.
[71] L. Hunt,et al. Influence of immunosuppressive therapy on lipoprotein(a) and other lipoproteins following renal transplantation. , 1997, Nephron.
[72] A. Hartmann,et al. Bilateral Pharmacokinetic Interaction Between Cyclosporine A and Atorvastatin in Renal Transplant Recipients , 2001, American Journal of Transplantation.
[73] T. Hamazaki,et al. Effect of fish oil concentrate on risk factors of cardiovascular complications in renal transplantation. , 1989, Transplantation proceedings.
[74] J. Newburger,et al. Niacin treatment of hypercholesterolemia in children. , 1993, Pediatrics.
[75] G. Duggin,et al. The effect of food and cholestyramine on the absorption of cyclosporine in cardiac transplant recipients. , 1988, Transplantation proceedings.
[76] B. Chanu,et al. Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and B. , 1985, Atherosclerosis.
[77] P. Stenvinkel,et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. , 1999, Kidney international.
[78] I. Rosenberg,et al. Hyperhomocysteinemia and hypercholesterolemia associated with hypothyroidism in the third US National Health and Nutrition Examination Survey. , 2001, Atherosclerosis.
[79] P. Taylor,et al. Clinical and laboratory adverse effects associated with long-term, low-dose isotretinoin: incidence and risk factors. The Isotretinoin-Basal Cell Carcinomas Study Group. , 1993, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[80] M. James-Kracke,et al. Does cholestyramine interfere with cyclosporine absorption? A prospective study in renal transplant patients. , 1995, ASAIO journal.
[81] M. Maioli,et al. Reduction of Albumin Excretion Rate in Normotensive Microalbuminuric Type 2 Diabetic Patients During Long-Term Simvastatin Treatment , 1997, Diabetes Care.
[82] T. Fraker,et al. Review: the effects of antihypertensive agents on serum lipids. , 1996, The American journal of the medical sciences.
[83] G. Kostner,et al. Serum concentrations of Lp(a) and other lipoprotein parameters in heavy alcohol consumers. , 1982, Annals of nutrition & metabolism.
[84] L. Wilkins. Plasma Lipid Distributions in Selected North American Populations: The Lipid Research Clinics Program Prevalence Study THE LIPID RESEARCH CLINICS PROGRAM EPIDEMIOLOGY COMMITTEE , 1979, Circulation.
[85] Robert M. Anderson,et al. Prevention or delay of type 2 diabetes. , 2004, Diabetes care.
[86] Ethan M Balk,et al. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[87] N. Wenger. Lipid metabolism, physical activity, and postmenopausal hormone therapy. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[88] M. Stegall,et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. , 2000, Transplantation.
[89] M. Byrne,et al. A prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone. , 1996, Clinical nephrology.
[90] N. Ertel,et al. Postsurgical reduction of serum lipoproteins: interleukin-6 and the acute-phase response. , 1998, The Journal of laboratory and clinical medicine.
[91] D. Maclean,et al. The prevalence of hyperlipidemia in women and its association with use of oral contraceptives, sex hormone replacement therapy and nonlipid coronary artery disease risk factors. Canadian Heart Health Surveys Research Group. , 1999, The Canadian journal of cardiology.
[92] O. Devuyst,et al. Deterioration in renal function associated with fibrate therapy. , 2001, Clinical nephrology.
[93] Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. , 1995, The American journal of cardiology.
[94] W. Brown. Cholesterol lowering in atherosclerosis. , 2000, The American journal of cardiology.
[95] C. F. Anderson,et al. Weight change and serum lipoproteins in recipients of renal allografts. , 1992, Mayo Clinic proceedings.
[96] J. Vollmar,et al. Effect of bezafibrate during 4.5 years of treatment of hyperlipoproteinaemia. , 1985, Atherosclerosis.
[97] Margret Arnadottir,et al. Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients. , 1994, Nephron.
[98] J. Guichard,et al. Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation , 1992, European Journal of Clinical Pharmacology.
[99] R. McPherson,et al. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. , 1998, The American journal of cardiology.
[100] M. Taskinen,et al. Changes in serum lipoprotein pattern induced by acute infections. , 1988, Metabolism: clinical and experimental.
[101] D. Hricik,et al. Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia. , 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[102] J. Mann,et al. Treatment of hyperlipidaemia in patients on chronic haemodialysis. , 1978, British medical journal.
[103] Z. Massy,et al. Dyslipidaemia and the progression of renal disease in chronic renal failure patients. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[104] J. Larosa,et al. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. , 1999, JAMA.
[105] J. Joven,et al. Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. , 1990, The New England journal of medicine.
[106] S. Nielsen,et al. The clinical course of renal function in NIDDM patients with normo‐ and microalbuminuria , 1997, Journal of internal medicine.
[107] A. Hoitsma,et al. The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. , 1995, Journal of the American Society of Nephrology : JASN.
[108] Meehyung Cho,et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. , 2002, The American journal of cardiology.
[109] C. Zoccali,et al. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. , 2002, Kidney international.
[110] L Fritsche,et al. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine‐treated kidney transplant recipients , 1999, Clinical pharmacology and therapeutics.
[111] H. Vierhapper,et al. Low-density lipoprotein cholesterol in subclinical hypothyroidism. , 2000, Thyroid : official journal of the American Thyroid Association.
[112] F. Port,et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[113] Z. Varghese,et al. Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. , 1993, Kidney international.
[114] B. Kasiske,et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. , 2000, Journal of the American Society of Nephrology : JASN.
[115] L. G. Wickboldt,et al. Pancreatitis associated with isotretinoin-induced hypertriglyceridemia. , 1987, Annals of internal medicine.
[116] H. Wedel,et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[117] R. Abbate,et al. Risk factors for cardiovascular disease in renal transplant recipients: new insights , 2000, Transplant international : official journal of the European Society for Organ Transplantation.
[118] R. Calne,et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. , 1999, Transplantation.
[119] M. Uusitupa,et al. Plant stanol esters affect serum cholesterol concentrations of hypercholesterolemic men and women in a dose-dependent manner. , 2000, The Journal of nutrition.
[120] P. Drouin,et al. [Action of fenofibrate in hypercholesterolemic children. 18-month follow-up]. , 1984, Presse medicale.
[121] U. Christians,et al. Comparison of pravastatin and lovastatin in renal transplant patients receiving cyclosporine. , 1996, Transplantation proceedings.
[122] Detection. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) , 1997 .
[123] J. Pimentel,et al. Therapy of post-renal transplantation hyperlipidaemia: comparative study with simvastatin and fish oil. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[124] G. Kaysen,et al. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[125] G. Chertow,et al. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[126] O. Devuyst,et al. Creatinine rise after fibrate therapy in renal graft recipients , 1993, The Lancet.
[127] R. Poveda,et al. Goodpasture syndrome during the course of a Schönlein-Henoch purpura. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[128] I. Holme,et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial , 2003, The Lancet.
[129] P. Neuvonen,et al. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid , 1998, Clinical pharmacology and therapeutics.
[130] H. Hohage,et al. ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients. , 1999, Hypertension.
[131] H. Wedel,et al. Plasma levels of lipoprotein (a) do not predict progression of human chronic renal failure. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[132] G. Mayer,et al. Low dose angiotensin converting enzyme inhibition and glomerular permselectivity in renal transplant recipients. , 1997, Kidney international.
[133] A. Gotto,et al. Pleiotropic effects of statins: do they matter? , 2001, Current opinion in lipidology.
[134] S. Grundy,et al. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. , 2002, Circulation.
[135] G. Duvel. The study group. , 1980 .
[136] J. Achard,et al. [Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency]. , 1999, Nephrologie.
[137] H. Pan,et al. Single‐Dose Pharmacokinetics of Pravastatin and Metabolites in Patients with Renal Impairment , 1992, Journal of clinical pharmacology.
[138] A. Martínez‐Castelao,et al. Double-blind, crossover, comparative study of doxazosin and enalapril in the treatment of hypertension in renal transplant patients under cyclosporine immunosuppression. , 2002, Transplantation proceedings.
[139] A. Watson,et al. Hyperlipidaemia, diet and simvastatin therapy in steroid-resistant nephrotic syndrome of childhood , 1996, Pediatric Nephrology.
[140] A. von Eckardstein,et al. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. , 1998, European heart journal.
[141] R. Weinshilboum,et al. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. , 1997, Archives of internal medicine.
[142] C. Braas,et al. Risk factors for hyperlipidemia in long-term pediatric renal transplant recipients , 2000, Pediatric Nephrology.
[143] B. Vergès. Dyslipidaemia in diabetes mellitus. Review of the main lipoprotein abnormalities and their consequences on the development of atherogenesis. , 1999, Diabetes & metabolism.
[144] K. Alberti,et al. Renal function and insulin sensitivity during simvastatin treatment in Type 2 (non-insulin-dependent) diabetic patients with microalbuminuria , 1993, Diabetologia.
[145] H. Wedel,et al. Plasma levels of lipoprotein (a) do not predict progression of human chronic renal failure , 1996 .
[146] J. Desager,et al. Effect of hemodialysis on plasma kinetics of fenofibrate in chronic renal failure. , 1982, Nephron.
[147] C. V. Strihou,et al. Hypertension after renal transplantation. , 1976, British medical journal.
[148] B. Kaufmann,et al. Pharmacokinetics of bezafibrate after single and multiple doses in the presence of renal failure , 1980, Klinische Wochenschrift.
[149] D. Sica,et al. The pharmacokinetics of pravastatin in patients on chronic hemodialysis , 1997, European Journal of Clinical Pharmacology.
[150] M. Haubitz,et al. C-reactive protein and chronic Chlamydia pneumoniae infection--long-term predictors for cardiovascular disease and survival in patients on peritoneal dialysis. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[151] N. Rifai,et al. Utility of direct measurement of low-density lipoprotein cholesterol in dyslipidemic pediatric patients. , 1998, Archives of pediatrics & adolescent medicine.
[152] J. Aufenanger,et al. Untersuchungen zum Lipid- und Lipoproteinstoffwechsel beim Menschen nach operativen Eingriffen , 2004, Langenbecks Archiv für Chirurgie.
[153] G. Beck,et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. , 1997, Kidney international.
[154] B. Kasiske,et al. Effects of Antihypertensive Therapy on Serum Lipids , 1995, Annals of Internal Medicine.
[155] V. Stevens,et al. Effects of diet and sexual maturation on low-density lipoprotein cholesterol during puberty: the Dietary Intervention Study in Children (DISC). , 1997, Circulation.
[156] F. Locatelli,et al. Prospective, randomised, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency , 1991, The Lancet.
[157] G. Siest,et al. Biological variations in hyperlipidemic children and adolescents treated with fenofibrate. , 1981, Clinica chimica acta; international journal of clinical chemistry.
[158] A. Keech,et al. Effect of Pravastatin on Coronary Disease Events in Subgroups Defined by Coronary Risk Factors: The Prospective Pravastatin Pooling Project , 2000, Circulation.
[159] J. Kopple,et al. National kidney foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[160] R. Moore,et al. Abnormal lipid and lipoprotein profiles following renal transplantation. , 1993, Transplantation proceedings.
[161] R. Klein,et al. The 10-year incidence of renal insufficiency in people with type 1 diabetes. , 1999, Diabetes care.
[162] R. Gibey,et al. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. , 2000, Journal of the American Society of Nephrology : JASN.
[163] P. Neuvonen,et al. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations , 1998, Clinical pharmacology and therapy.
[164] F. Oppenheimer,et al. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. , 2000, Transplantation.
[165] N. Ichimaru,et al. Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. , 2001, Atherosclerosis.
[166] R. Scheig,et al. Ethanol-induced hypertriglyceridemia. Prevalence and contributing factors. , 1978, The American journal of clinical nutrition.
[167] B. Morgenstern,et al. Lipid levels following renal transplantation in pediatric recipients. , 1994, Transplantation proceedings.
[168] Kdoqi Disclaimer. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[169] F. Scanferla,et al. Associated effect of hepatic hydroxymethylglutaryl coenzyme A reductase + angiotensin converting enzyme inhibitors on the progression of renal failure in hypertensive subjects. , 1991, American journal of hypertension.
[170] P. Malfertheiner,et al. Hyperlipidemia in acute pancreatitis , 1995 .
[171] D. Cutler,et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. , 2000, British journal of clinical pharmacology.
[172] R. Levy,et al. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.
[173] H. Koistinen,et al. Dyslipidemia and a reversible decrease in insulin sensitivity induced by therapy with 13‐cis‐retinoic acid , 2001, Diabetes/metabolism research and reviews.
[174] R. Suresh,et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. , 2003, The American journal of cardiology.
[175] W. Weimar,et al. Conversion from cyclosporine A to azathioprine treatment improves LDL oxidation in kidney transplant recipients. , 1997, Kidney international.
[176] A. Mimran,et al. Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants. , 1993, Kidney international.
[177] G. Schonfeld,et al. Fat-soluble vitamin concentrations in hypercholesterolemic children treated with colestipol. , 1980, Pediatrics.
[178] H. E. Norbeck,et al. Clinical pharmacokinetics of bezafibrate in patients with impaired renal function , 2004, European Journal of Clinical Pharmacology.
[179] A. Mazzu,et al. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin , 2000, Clinical pharmacology and therapeutics.
[180] S Kamen,et al. The task force. , 1976, Journal of hospital dental practice.
[181] C. Stehouwer,et al. Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non‐insulin‐dependent diabetes mellitus? , 1997, European journal of clinical investigation.
[182] J. Mckenney,et al. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.
[183] M. Kuske,et al. Assignment1 of the human PHLDA1 gene to chromosome 12q15 by radiation hybrid mapping , 2000, Cytogenetic and Genome Research.
[184] B. Zinman,et al. Effect of intensive therapy on early macrovascular disease in young individuals with type 1 diabetes. A systematic review and meta-analysis. , 1999, Diabetes care.
[185] B. Kasiske,et al. Transient reductions in serum cholesterol after renal transplantation. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[186] P Langenberg,et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. , 2001, Archives of internal medicine.
[187] M. Pfeffer,et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[188] S. Ganesh,et al. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. , 2001, Journal of the American Society of Nephrology : JASN.
[189] P. Raggi,et al. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. , 2002, Kidney international.
[190] R. Margreiter,et al. Comparison of progression of macrovascular diseases after kidney or pancreas and kidney transplantation in diabetic patients with end-stage renal disease , 2000, Diabetologia.
[191] Qiuwei Xu,et al. Bile acid binding to sevelamer HCl. , 2002, Kidney international.
[192] C. Wanner,et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. , 1999, Kidney international.
[193] S. Aakhus,et al. Cardiovascular morbidity and risk factors in renal transplant patients. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[194] R. Marcén,et al. Nandrolone decanoate reduces serum lipoprotein(a) concentrations in hemodialysis patients. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[195] M. Sentí,et al. Influence of intermediate-density lipoproteins on the accuracy of the Friedewald formula. , 1991, Clinical chemistry.
[196] F. Fuchs,et al. Safety and efficacy of simvastatin for hyperlipidemia in renal transplant recipients: a double-blind, randomized, placebo-controlled study. , 2001, Transplantation proceedings.
[197] S. Olson,et al. Erythromycin Coadministration Increases Plasma Atorvastatin Concentrations , 1999, Journal of clinical pharmacology.
[198] T. Cundy,et al. Renal function changes in diabetic nephropathy induced by bezafibrate. , 1996, Nephron.
[199] N Rifai,et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. , 2001, JAMA.
[200] M. Lishner,et al. Plasma lipids and the progression of nephropathy in diabetes mellitus type II: effect of ACE inhibitors. , 1995, Kidney international.
[201] I. Rosenberg,et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[202] V. Myllylä,et al. Plasma HDL cholesterol in epileptics with elevated triglyceride and cholesterol , 1979, Acta neurologica Scandinavica.
[203] A. Gaber,et al. Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study. , 1998, Transplantation.
[204] C. Pollock,et al. Hyperlipidemia in Renal Transplant Recipients: Natural History and Response to Treatment , 1994, Medicine.
[205] E. Ingulli,et al. THE BENEFICIAL EFFECTS OF STEROID WITHDRAWAL ON BLOOD PRESSURE AND LIPID PROFILE IN CHILDREN POSTTRANSPLANTATION IN THE CYCLOSPORINE ERA , 1993, Transplantation.
[206] F. Chiarelli,et al. Changes in serum lipids and lipoproteins in epileptic children treated with anticonvulsants , 1997, Journal of paediatrics and child health.
[207] M. Friger,et al. Usefulness of lipoprotein changes during acute coronary syndromes for predicting postdischarge lipoprotein levels. , 2002, The American journal of cardiology.
[208] R. Brook. Mechanism of differential effects of antihypertensive agents on serum lipids , 2000, Current hypertension reports.
[209] J. Gore,et al. Validity of serum total cholesterol level obtained within 24 hours of acute myocardial infarction. , 1984, The American journal of cardiology.
[210] H. Wieland,et al. Hypertriglyceridaemia Secondary to Liver Disease , 1974, European journal of clinical investigation.
[211] J. D. Karkas,et al. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. , 1993, Nephron.
[212] R. West,et al. LONG-TERM FOLLOW-UP OF CHILDREN WITH FAMILIAL HYPERCHOLESTEROLÆMIA TREATED WITH CHOLESTYRAMINE , 1980, The Lancet.
[213] Nina Singh,et al. Dyslipidaemia in HIV-infected patients: association with adherence to potent antiretroviral therapy , 2001, International journal of STD & AIDS.
[214] L. Hamm,et al. Introduction: National Kidney Foundation 50th anniversary commemorative issue , 2000 .
[215] J W Erdman,et al. AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. , 2000, Circulation.
[216] M. Rieser,et al. Lack of a Clinically Significant Pharmacokinetic Interaction between Fenofibrate and Pravastatin in Healthy Volunteers , 2000, Journal of clinical pharmacology.
[217] A. Gotto. Ongoing clinical trials of statins. , 2001, The American journal of cardiology.
[218] M. Ravid,et al. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. , 1998, Archives of internal medicine.
[219] G. Steiner. Lipid intervention trials in diabetes. , 2000, Diabetes care.
[220] O. Tomonaga,et al. Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients , 1997, Diabetologia.
[221] Z. Varghese,et al. Low-dose simvastatin is safe in hyperlipidaemic renal transplant patients. , 1993, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[222] Vergès Bl. Dyslipidaemia in diabetes mellitus. Review of the main lipoprotein abnormalities and their consequences on the development of atherogenesis. , 1999 .
[223] S. Grundy,et al. Variability in cholesterol content and physical properties of lipoproteins containing apolipoprotein B-100. , 1993, Atherosclerosis.
[224] U. Christians,et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine‐treated kidney graft patients after multiple doses , 1997, Clinical pharmacology and therapeutics.
[225] AndrewJ. S. Coats. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.
[226] P. Malfertheiner,et al. Hyperlipidemia in acute pancreatitis. Relationship with etiology, onset, and severity of the disease. , 1991, International journal of pancreatology : official journal of the International Association of Pancreatology.
[227] H. Büller,et al. Short-Term Efficacy and Safety of Pravastatin in 72 Children with Familial Hypercholesterolemia , 1996, Pediatric Research.
[228] H. Lageder. [Comparative double-blind investigation of bezafibrate and clofibrate in patients with primary hyperlipoproteinaemia]. , 1980, Wiener klinische Wochenschrift.
[229] R. Olson,et al. Atherogenesis in children: implications for the prevention of atherosclerosis. , 2000, Advances in pediatrics.
[230] W. K. Henry,et al. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[231] C. Wanner,et al. Immunosuppression enhances atherogenicity of lipid profile after transplantation. , 1999, Kidney international. Supplement.
[232] B. Kasiske,et al. Lovastatin treatment of hypercholesterolemia in renal transplant recipients. , 1990, Transplantation.
[233] M. Taskinen,et al. Alcohol-induced changes in serum lipoproteins and in their metabolism. , 1987, American heart journal.
[234] P. Neuvonen,et al. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid , 1996, Clinical pharmacology and therapeutics.
[235] C. Luley,et al. Serum homocysteine increases after therapy with fenofibrate or bezafibrate , 1999, The Lancet.
[236] G. Schernthaner,et al. Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria , 1996, Diabetologia.
[237] A. Nayır,et al. Arterial changes in paediatric haemodialysis patients undergoing renal transplantation. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[238] James C. Beyer,et al. Coronary Disease Among United States Soldiers Killed in Action in Korea: Preliminary Report , 1953 .
[239] P. Macfarlane,et al. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. , 1999, The American journal of cardiology.
[240] P A Wolf,et al. Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. , 2001, Circulation.
[241] J. Hokanson,et al. Hypertriglyceridemia as a cardiovascular risk factor. , 1998, The American journal of cardiology.
[242] L. Squassante,et al. The effects of lacidipine on the steady/state plasma concentrations of simvastatin in healthy subjects. , 2001, British journal of clinical pharmacology.
[243] S. Aakhus,et al. Hyperlipidaemia in renal transplant patients , 1996, Journal of internal medicine.
[244] C. Packard,et al. A simultaneous study of the metabolism of apolipoprotein B and albumin in nephrotic patients. , 1998, Kidney international.
[245] J. Gallin,et al. Serum lipids in infection. , 1969, The New England journal of medicine.
[246] W. März,et al. Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis , 1999 .
[247] P. Neuvonen,et al. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole , 1998, Clinical pharmacology and therapeutics.
[248] J. Jais,et al. Lipodystrophic Syndromes and Hyperlipidemia in a Cohort of HIV‐1‐Infected Patients Receiving Triple Combination Antiretroviral Therapy With a Protease Inhibitor , 2001, Journal of acquired immune deficiency syndromes.
[249] R. Hené,et al. Hypertension after renal transplantation. Calcium channel or converting enzyme blockade? , 1995, Hypertension.
[250] R. Suresh,et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. , 2002, Journal of the American College of Cardiology.
[251] P. Neuvonen,et al. Effect of itraconazole on the pharmacokinetics of atorvastatin , 1998, Clinical pharmacology and therapeutics.
[252] Lisa Anne Hendricks,et al. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. , 1995, The American journal of cardiology.
[253] P. Thompson,et al. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. , 1989, JAMA.
[254] E. Mutschler,et al. Gemfibrozil absorption and elimination in kidney and liver disease , 1990, Klinische Wochenschrift.
[255] A. Luzier,et al. Potential interaction between troglitazone and atorvastatin , 2000, Journal of clinical pharmacy and therapeutics.
[256] A. Moustapha,et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. , 1998, Circulation.
[257] K. Rootwelt,et al. Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril. , 2001, Transplantation.
[258] G. Cazzolato,et al. Changes in the composition and physico-chemical characteristics of serum lipoproteins during ethanol-induced lipaemia in alcoholic subjects. , 1975, Metabolism: clinical and experimental.
[259] J F Cornhill,et al. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. , 1999, JAMA.
[260] R. Munford. Statins and the acute-phase response. , 2001, The New England journal of medicine.
[261] A. Kumar,et al. Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection , 2001, Clinical transplantation.
[262] A. Allegra,et al. Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy , 2000, Clinical pharmacology and therapeutics.
[263] S. Hall,et al. The interaction of diltiazem with simvastatin , 2000, Clinical pharmacology and therapeutics.
[264] M. de Lorgeril,et al. The long-term effects of the lipid-lowering agent fenofibrate in hyperlipidemic heart transplant recipients. , 1994, Transplantation.
[265] M. Haneda,et al. Progression of diabetic nephropathy. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[266] E. Vartiainen,et al. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. , 1995, The New England journal of medicine.
[267] S. Yusuf. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .
[268] P. Neuvonen,et al. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations , 2000, Clinical pharmacology and therapeutics.
[269] J. Kovarik,et al. Pharmacokinetic and Pharmacodynamic Assessments of HMG‐CoA Reductase Inhibitors When Coadministered with Everolimus , 2002, Journal of clinical pharmacology.
[270] M. Yacoub,et al. Maxepa versus bezafibrate in hyperlipidemic cardiac transplant recipients. , 1992, The American journal of cardiology.
[271] P. Wilson,et al. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control study. , 1995, Atherosclerosis.
[272] D. Batlle,et al. Improvement of Lipid Abnormalities Associated with Proteinuria Using Fosinopril, an Angiotensin-Converting Enzyme Inhibitor , 1993, Annals of Internal Medicine.
[273] V. Hachinski,et al. Serum lipids after stroke , 1987, Neurology.
[274] C. Packard,et al. Metabolism of apolipoprotein B-containing lipoproteins in subjects with nephrotic-range proteinuria. , 1991, Kidney international.
[275] P. Kris-Etherton,et al. Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis. , 1999, The American journal of clinical nutrition.
[276] J. Marples,et al. Comparative study of once and 3-times daily regimens of bezafibrate in patients with primary hyperlipoproteinaemia. , 1981, Current medical research and opinion.
[277] K. Matsuyama,et al. Drug interaction between simvastatin and cholestyramine in vitro and in vivo. , 1996, Biological & pharmaceutical bulletin.
[278] R. Collins,et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.
[279] C. Glueck,et al. Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone. , 1997, JAMA.
[280] Meilin Liu,et al. Influence of renal function on the pharmacokinetics of cerivastatin in normocholesterolemic adults , 2000, European Journal of Clinical Pharmacology.
[281] V. Fuster,et al. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. , 2001, Circulation.
[282] Robert M. Anderson,et al. 5. Prevention or Delay of Type 2 Diabetes , 2016, Diabetes Care.
[283] V. Fuster,et al. AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. , 2001, Journal of the American College of Cardiology.
[284] J. García-Puig,et al. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. , 1996, Journal of human hypertension.
[285] C. L. Williams,et al. Plant stanol ester and bran fiber in childhood: effects on lipids, stool weight and stool frequency in preschool children. , 1999, Journal of the American College of Nutrition.
[286] M. Vohl,et al. Influence of LDL receptor gene mutation and apo E polymorphism on lipoprotein response to simvastatin treatment among adolescents with heterozygous familial hypercholesterolemia. , 2002, Atherosclerosis.
[287] P. Kwiterovich. Diagnosis and management of familial dyslipoproteinemia in children and adolescents. , 1990, Pediatric clinics of North America.
[288] D. Capuzzi,et al. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. , 1998, The American journal of cardiology.
[289] B. Kasiske,et al. Cardiovascular disease after renal transplantation. , 2000, Journal of the American Society of Nephrology : JASN.
[290] J. Viikari,et al. Intake and indicators of iron and zinc status in children consuming diets low in saturated fat and cholesterol: the STRIP baby study. Special Turku Coronary Risk Factor Intervention Project for Babies. , 1997, The American journal of clinical nutrition.
[291] K. Schärer,et al. Lipoprotein(a) Serum Levels and Apolipoprotein(a) Phenotypes in Children with Chronic Renal Disease , 1993, Pediatric Research.
[292] W. Jaross,et al. Pharmacokinetics and Pharmacodynamics of Fluvastatin in Heart Transplant Recipients Taking Cyclosporine A , 2001, Journal of cardiovascular pharmacology and therapeutics.
[293] C. Alderman. Possible Interaction between Nefazodone and Pravastatin , 1999, The Annals of pharmacotherapy.
[294] C. Alvarez,et al. Lipids, lipoproteins, and apoproteins in serum during infection. , 1986, Clinical chemistry.
[295] J. Joven,et al. How soon after myocardial infarction should plasma lipid values be assessed? , 1985, British medical journal.
[296] D. Abramowicz,et al. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[297] J. Després,et al. Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[298] L. Agodoa,et al. United States Renal Data System (USRDS). , 2000, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.
[299] J. Viikari,et al. Regulation of growth of 7- to 36-month-old children by energy and fat intake in the prospective, randomized STRIP baby trial. , 1997, Pediatrics.
[300] P. Hopkins,et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. , 1999, JAMA.
[301] S. Takahara,et al. Randomized prospective study of effects of benazepril in renal transplantation: an analysis of safety and efficacy , 2002, Clinical and Experimental Nephrology.
[302] P. Neuvonen,et al. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate , 2001, Clinical pharmacology and therapeutics.
[303] P. Jungers,et al. Hyperhomocysteinemia is associated with atherosclerotic occlusive arterial accidents in predialysis chronic renal failure patients. , 1997, Mineral and electrolyte metabolism.
[304] Z. Massy,et al. Hyperhomocysteinaemia: a significant risk factor for cardiovascular disease in renal transplant recipients. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[305] J. Vollmar,et al. Bezafibrate: Lack of effect on creatinine excretion and muscular proteins , 1982, Research in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie.
[306] G. Schlierf,et al. Langzeittherapie der familiären Hypercholesterinämie bei Jugendlichen mit Colestipol: Versorgungszustand mit Mineralstoffen und Vitaminen , 1985, Klinische Wochenschrift.
[307] J. Viikari,et al. Growth until 3 years of age in a prospective, randomized trial of a diet with reduced saturated fat and cholesterol. , 1997, Pediatrics.
[308] C. Ballantyne,et al. Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients. , 2001, Transplantation.
[309] J. T. Clarke,et al. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group. , 1996, Pediatrics.
[310] M. Elisaf,et al. Evaluation of five methods for determining low-density lipoprotein cholesterol (LDL-C) in hemodialysis patients(1). , 2001, Clinical biochemistry.
[311] Michael C. Fiore,et al. A Clinical Practice Guideline for Treating Tobacco Use and Dependence A US Public Health Service Report , 2000 .
[312] W. Kupin,et al. COMPLETE REPLACEMENT OF METHYLPREDNISOLONE BY AZATHIOPRINE IN CYCLOSPORINE‐TREATED PRIMARY CADAVERIC RENAL TRANSPLANT RECIPIENTS1 Pressented at the 6th Annual Meeting of the American Society of Transplant Physicians, May 1987, Chicago, IL , 1988, Transplantation.
[313] H. Crijns,et al. Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND I , 2000, The American journal of cardiology.
[314] G. Balady,et al. Exercise Training and Bleed Viscosity in Patients With Ischemic Heart Disease , 1995 .
[315] A. Levey. Controlling the epidemic of cardiovascular disease in chronic renal disease: where do we start? , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[316] R. Stubbs,et al. Single‐dose pharmacokinetics of 14C‐lovastatin in chronic renal failure , 1991, Clinical pharmacology and therapeutics.
[317] J. Zazgornik,et al. Similar rate of progression in the predialysis phase in type I and type II diabetes mellitus. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[318] B. McCrindle,et al. Acceptability and compliance with two forms of cholestyramine in the treatment of hypercholesterolemia in children: a randomized, crossover trial. , 1997, The Journal of pediatrics.
[319] Uk-Prospective-Diabetes-Study-Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.
[320] P. Neuvonen,et al. Grapefruit juice—simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG‐CoA reductase inhibitors , 1998, Clinical pharmacology and therapeutics.
[321] A. Goldberg,et al. Control of clofibrate toxicity in uremic hypertriglyceridemia , 1977, Clinical pharmacology and therapeutics.
[322] S. Oparil,et al. Physical activity and cardiovascular health , 1996 .
[323] P. Neuvonen,et al. Plasma concentrations of active simvastatin acid are increased by gemfibrozil , 2000, Clinical pharmacology and therapeutics.
[324] E. Liberopoulos,et al. The incidence of thyroid function abnormalities in patients attending an outpatient lipid clinic. , 1999, Thyroid : official journal of the American Thyroid Association.
[325] K. Schenck-Gustafsson,et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. , 2001, Circulation.
[326] Blood lipid measurements: Variations and practical utility , 1992, JAMA.
[327] P. Neuvonen,et al. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. , 1998, British journal of clinical pharmacology.
[328] C. Wanner,et al. Simvastatin in nephrotic syndrome , 1999 .
[329] C. Barbagallo,et al. Carotid atherosclerosis in renal transplant recipients: relationships with cardiovascular risk factors and plasma lipoproteins. , 1999, Transplantation.
[330] J. Dillon. The quantitative relationship between treated blood pressure and progression of diabetic renal disease. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[331] Ncep Expert Panel on Blood Cholesterol Levels in Childr Adolescents. National Cholesterol Education Program (NCEP): highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. , 1992, Pediatrics.
[332] S. C. Forland,et al. The Effect of Renal Function on the Pharmacokinetics of Gemfibrozil , 1987, Journal of clinical pharmacology.
[333] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[334] S. Rössner,et al. Fenofibrate therapy of hyperlipoproteinaemia. A dose-response study and a comparison with clofibrate. , 1981, Atherosclerosis.
[335] J. Hermans,et al. Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: a randomized study. , 1997, Journal of the American Society of Nephrology : JASN.
[336] S. Grundy,et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. , 1999, Circulation.
[337] Olli T. Raitakari,et al. Increased Aortic Intima-Media Thickness: A Marker of Preclinical Atherosclerosis in High-Risk Children , 2001, Circulation.
[338] H. Parving,et al. The course of kidney function in Type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy , 1993, Diabetologia.
[339] R. Withers,et al. Exercise training and blood lipids in hyperlipidemic and normolipidemic adults: A meta-analysis of randomized, controlled trials , 1999, European Journal of Clinical Nutrition.
[340] A. Williams,et al. The short term effects of bezafibrate on the hypertriglyceridaemia of moderate to severe uraemia. , 1984, British journal of clinical pharmacology.
[341] M. Benfield,et al. Sequential analysis of the lipid profile of children post-renal transplantation. , 1998, Pediatric transplantation.
[342] M. Eriksson,et al. Low‐density lipoprotein metabolism and its association to plasma lipoprotein(a) in the nephrotic syndrome , 1997, European journal of clinical investigation.
[343] T. Strom,et al. DELAYED OMEGA‐3 FATTY ACID SUPPLEMENTS IN RENAL TRANSPLANTATION A DOUBLE‐BLIND, PLACEBO‐CONTROLLED STUDY , 1995, Transplantation.
[344] P. Stenvinkel,et al. Elevated serum levels of soluble adhesion molecules predict death in pre-dialysis patients: association with malnutrition, inflammation, and cardiovascular disease. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[345] G. Bosco,et al. Diet only and diet plus simvastatin in the treatment of heterozygous familial hypercholesterolemia in childhood. , 1997, Drugs under experimental and clinical research.